Superiority of Rituximab Over Mycophenolate Mofetil in the Treatment of Pemphigus Vulgaris: A Step Further in Its Approval as a First-Line Treatment?

Abstract

Keywords

pemphigus rituximab mycophenolate mofetil treatment

Get full access to this article

View all access options for this article.

References

Atzmony

Hodak

Leshem

et al. The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):264-271.doi:10.1016/j.jaad.2015.04.038

26088689

Joly

Maho-Vaillant

Prost-Squarcioni

et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040.doi:10.1016/S0140-6736(17)30070-3

28342637

Werth

VP.

Joly

Mimouni

et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med Overseas Ed. 2021;384(24):2295-2305.doi:10.1056/NEJMoa2028564

34097368

Mignard

Maho-Vaillant

Golinski

M-L

et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatol. 2020;156(5):545-552.doi:10.1001/jamadermatol.2020.0290

32186656

Lunardon

Tsai

KJ.

Propert

et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031-1036.doi:10.1001/archdermatol.2012.1522

22710375